Trials / Completed
CompletedNCT00079742
A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis
A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety and Efficacy of Nutropin AQ [Somatropin (DNA Origin) Injection] for the Treatment of Growth Restriction in Children With Cystic Fibrosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 5 Years – 13 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, multicenter, randomized, controlled, open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously (SC) daily in prepubertal children with CF and growth restriction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nutropin AQ [somatropin (DNA origin) injection] |
Timeline
- Start date
- 2003-09-01
- Completion
- 2007-05-01
- First posted
- 2004-03-16
- Last updated
- 2008-06-09
Source: ClinicalTrials.gov record NCT00079742. Inclusion in this directory is not an endorsement.